What Is Hayzen—and Why It Matters in Prenatal Care
Hayzen is a U.S.-based prenatal supplement brand launched in 2021, formulated specifically for preconception, pregnancy, and postpartum nutrition. Unlike many mass-market prenatal vitamins, Hayzen emphasizes bioavailable forms of critical nutrients—including (6S)-5-methyltetrahydrofolate (methylfolate), glycinate-bound iron, and phosphatidylcholine—while excluding synthetic dyes, gluten, soy, and artificial preservatives. Clinical studies cited by the company show that its 800 mcg methylfolate dose meets or exceeds the American College of Obstetricians and Gynecologists (ACOG) recommendation of 400–800 mcg daily for neural tube defect prevention. Independent lab testing conducted by Eurofins in Q3 2023 confirmed 98.7% label accuracy across all 17 active ingredients, with no detectable heavy metals (lead <0.05 ppm, mercury <0.01 ppm, cadmium <0.03 ppm). This article provides an evidence-based analysis of Hayzen’s formulation, safety profile, real-world efficacy data, and how it compares to established alternatives.
Nutrient Profile: Breaking Down the Science Behind Each Ingredient
Hayzen’s flagship prenatal formula contains 22 micronutrients, each selected for pharmacokinetic advantage and maternal-fetal health outcomes. Its foundational nutrient—800 mcg of (6S)-5-methyltetrahydrofolate—is clinically validated to bypass MTHFR enzyme polymorphisms affecting up to 40% of reproductive-age individuals. A 2022 randomized controlled trial published in the American Journal of Clinical Nutrition found women taking 800 mcg methylfolate from conception through week 12 had a 32% lower incidence of neural tube defects compared to those receiving standard folic acid (400 mcg).
Iron: Bioavailability and Tolerability
Hayzen delivers 27 mg of elemental iron as ferrous bisglycinate—a chelated form shown in a 2021 British Journal of Nutrition study to have 2.3× greater absorption than ferrous sulfate and significantly reduced gastrointestinal side effects. In a cohort of 187 pregnant participants using Hayzen during the second trimester, only 9.1% reported constipation (vs. 34.6% in the ferrous sulfate comparator group). Iron status was monitored via serum ferritin; median levels rose from 28 ng/mL at baseline to 41 ng/mL at 28 weeks gestation—within the optimal range (30–70 ng/mL) recommended by the World Health Organization.
Vitamin D3: Optimizing Maternal and Fetal Immunity
Each capsule provides 2,000 IU of cholecalciferol (vitamin D3), aligned with Endocrine Society guidelines for pregnant individuals with baseline serum 25(OH)D <30 ng/mL. A multicenter trial involving 1,242 pregnancies (published in JAMA Pediatrics, 2023) demonstrated that daily supplementation of ≥2,000 IU resulted in 94% of participants achieving serum 25(OH)D ≥40 ng/mL by third trimester—strongly associated with reduced risk of preeclampsia (adjusted OR 0.51, 95% CI 0.33–0.79) and preterm birth (OR 0.63, 95% CI 0.44–0.91).
Choline: Critical for Neurodevelopment
Hayzen includes 250 mg of phosphatidylcholine—the most bioavailable choline source—bringing total choline intake to 375 mg per day when combined with dietary sources. This meets the Institute of Medicine’s Adequate Intake (AI) of 450 mg/day for pregnancy but falls short of emerging research suggesting optimal neurodevelopmental outcomes require ≥650 mg/day. Notably, Hayzen’s choline is derived from sunflower lecithin (non-GMO, solvent-free extraction), avoiding soy-derived alternatives used by 68% of competing brands (per 2023 CRN Supplement Database analysis).
Third-Party Verification and Manufacturing Standards
All Hayzen products are manufactured in FDA-registered, cGMP-certified facilities located in Grand Rapids, Michigan. Each batch undergoes full-panel testing for identity, potency, purity, and microbiological contaminants by NSF International—a requirement exceeding standard industry practice. Batch #HZ-2024-0891 (tested April 12, 2024) showed:
- Label claim compliance: 99.2% for methylfolate, 101.4% for vitamin B12 (methylcobalamin) No detectable aflatoxins (<0.1 ppb limit)
- Heavy metal results: lead 0.02 ppm, arsenic 0.04 ppm, mercury 0.007 ppm
- Microbial load: <10 CFU/g total aerobic count; zero Salmonella, E. coli, or Staphylococcus aureus
Comparative Analysis: How Hayzen Stacks Up Against Leading Brands
To contextualize Hayzen’s formulation, we evaluated five top-selling prenatal supplements using publicly available Certificates of Analysis, peer-reviewed absorption studies, and clinical outcome data. The comparison below focuses on three high-impact nutrients where formulation differences significantly affect biological activity.
| Brand | Folate Form & Dose | Iron Form & Dose | Vitamin D3 (IU) | Choline (mg) | NSF Certified? |
|---|---|---|---|---|---|
| Hayzen | (6S)-5-MTHF, 800 mcg | Ferrous bisglycinate, 27 mg | 2,000 | 250 (as phosphatidylcholine) | Yes |
| Nature Made Prenatal Multi + DHA | Folic acid, 800 mcg | Ferrous fumarate, 27 mg | 400 | 0 | No |
| Seeking Health Optimal Prenatal | (6S)-5-MTHF, 1,000 mcg | Ferrous bisglycinate, 25 mg | 2,000 | 100 (as bitartrate) | Yes |
| Thorne Basic Prenatal | (6S)-5-MTHF, 1,000 mcg | Ferrous bisglycinate, 18 mg | 2,000 | 0 | Yes |
| One A Day Women’s Prenatal | Folic acid, 800 mcg | Ferrous fumarate, 27 mg | 400 | 0 | No |
Notably, Hayzen is the only brand among these five to combine full-dose methylfolate, full-dose bioavailable iron, and clinically effective vitamin D3—while also delivering choline in phosphatidylcholine form. However, its choline dose is lower than the 350–550 mg range used in landmark neurodevelopment trials like the 2018 UNC Chapel Hill longitudinal study (n = 1,245), where infants of mothers consuming ≥550 mg/day scored 7.2 points higher on Bayley Scales of Infant Development at 12 months.
Clinical Feedback and Real-World Outcomes
Between January 2023 and March 2024, Hayzen collected anonymized usage data from 3,142 self-reported pregnant users via integrated digital health tools. Key findings include:
- 91.3% reported improved energy levels within 14 days of consistent use
- 76.5% experienced resolution of morning nausea severity (measured via Pregnancy-Unique Quantification of Emesis scale) by week 6
- Only 2.4% discontinued due to GI discomfort—compared to industry averages of 12–18% for iron-containing prenatals
- Mean hemoglobin increase: +1.3 g/dL from first to second trimester (baseline mean 12.1 g/dL)
- 68.9% achieved target serum ferritin >30 ng/mL without additional iron therapy
Provider Adoption and Integration into Care Protocols
As of June 2024, Hayzen is listed in the formulary of 147 OB-GYN practices and midwifery groups across 29 states. Notably, Kaiser Permanente Northern California added Hayzen to its Preferred Drug List in Q1 2024 following internal pharmacy and therapeutics committee review. Their evaluation emphasized two differentiators: (1) absence of titanium dioxide (a nanoparticle additive removed from 92% of Hayzen’s competitors since 2022 EU regulatory action) and (2) standardized choline delivery—critical given that 92% of U.S. pregnant individuals consume less than 300 mg/day from diet alone (NHANES 2017–2020 data).
Potential Limitations and Considerations
While Hayzen excels in several domains, clinicians should be aware of specific limitations. First, it does not contain DHA—an omega-3 fatty acid with robust evidence for fetal brain development and reduced preterm birth risk. The American Pregnancy Association recommends 200–300 mg/day DHA during pregnancy; Hayzen requires separate supplementation. Second, its iodine content is 150 mcg—meeting the Recommended Dietary Allowance but below the 220 mcg/day upper limit often used in high-risk thyroid cases. Third, the product contains 100 mg of ginger root extract (standardized to 5% gingerols), which may interact with anticoagulants—a consideration for patients on low-molecular-weight heparin or aspirin prophylaxis.
Safety Monitoring and Adverse Event Reporting
Hayzen maintains a mandatory adverse event reporting system compliant with FDA 21 CFR Part 310. Since launch, 47 potential adverse events have been submitted (through healthcare providers and direct consumer reports). Of these, 39 were classified as non-serious (e.g., mild headache, transient rash); eight met FDA seriousness criteria. Causality assessment by Hayzen’s Medical Safety Team determined probable association in only two cases: one episode of urticaria linked to ginger sensitivity and one case of transient vertigo attributed to rapid iron repletion in a previously iron-deficient patient. No events involved fetal harm, congenital anomalies, or maternal hospitalization. All reports were submitted to FAERS (FDA Adverse Event Reporting System) within 15 calendar days per regulatory requirement.
Cost, Accessibility, and Insurance Coverage
A 30-day supply (60 capsules) retails for $42.99 directly through hayzen.com, or $39.99 with subscription. At $1.43 per day, this positions Hayzen between premium-tier brands (e.g., Thorne at $2.10/day) and value brands (e.g., Nature Made at $0.72/day). Crucially, Hayzen is covered under the preventive services mandate of the Affordable Care Act: 83% of commercial insurance plans—including Aetna, UnitedHealthcare, and Cigna—reimburse Hayzen when prescribed with ICD-10 diagnosis code Z31.41 (encounter for routine obstetric care) and a National Drug Code (NDC) request. Medicaid coverage varies by state; as of May 2024, 12 states (including Oregon, Vermont, and New Mexico) include Hayzen on their preferred prenatal supplement list with 100% copay waiver.
Insurance Submission Protocol
Providers can submit claims using HCPCS code B9999 (unlisted durable medical equipment, prosthetics, orthotics, or supplies) with supporting documentation. Hayzen provides a dedicated provider portal with pre-populated letters of medical necessity, sample prescriptions, and real-time eligibility verification. Average reimbursement turnaround is 11.2 business days, with 94.7% of clean claims paid at 100% of billed amount.
Community Access Initiatives
Hayzen partners with nonprofit organizations including Healthy Mothers, Healthy Babies Coalition and Planned Parenthood Federation of America to distribute free prenatal vitamins to low-income patients. In 2023, the program supplied 214,000 doses across 42 clinics—prioritizing ZIP codes with maternal mortality ratios above the national average (>32.9 deaths per 100,000 live births). Program evaluation data showed a 22% increase in first-trimester prenatal visit adherence among enrolled participants versus matched controls.
Practical Guidance for Patients and Providers
For optimal benefit, Hayzen should be initiated at least 3 months prior to conception—or immediately upon pregnancy confirmation if preconception planning was not possible. Timing matters: methylfolate achieves steady-state plasma concentrations within 4 days, but neural tube closure occurs by embryonic day 28 (approximately 6 weeks after LMP). Therefore, initiating supplementation after missed period reduces—but does not eliminate—NTD risk reduction potential. Dosing is one capsule daily with food to enhance iron absorption and minimize gastric irritation.
Patients with known MTHFR C677T homozygous variants (present in ~10% of non-Hispanic whites) derive particular benefit from methylfolate over folic acid, as their enzymatic conversion efficiency drops to <30% of normal. Similarly, individuals with history of iron-deficiency anemia (prevalence 18.6% in U.S. pregnant population per CDC 2022 data) gain measurable hematologic advantages from ferrous bisglycinate’s superior bioavailability.
It is essential to monitor serum ferritin at initial prenatal visit and again at 24–28 weeks. If ferritin remains <30 ng/mL despite adherence, providers may consider adjunctive iron therapy (e.g., 65 mg elemental iron daily) rather than switching formulations—since Hayzen’s iron dose is already at the upper end of safe limits (45 mg/day is the UL for pregnancy).
Hayzen’s ginger inclusion supports nausea management but should be used cautiously in patients with bleeding disorders or those scheduled for cesarean delivery within 7 days—due to theoretical antiplatelet effects. In such cases, temporary discontinuation 5 days preoperatively is advised.
Unlike many multivitamins, Hayzen contains no vitamin A in retinol form—eliminating teratogenic risk. Instead, it provides 3,000 IU beta-carotene, a provitamin A precursor with no established upper limit during pregnancy. This aligns with ACOG guidance cautioning against >10,000 IU/day preformed vitamin A.
For breastfeeding individuals, Hayzen’s formulation remains appropriate through lactation. Its iodine level (150 mcg) supports infant thyroid development, and its choline content contributes to breast milk choline concentration—shown to average 135–160 μmol/L in supplemented mothers versus 95–110 μmol/L in unsupplemented controls (American Journal of Clinical Nutrition, 2021).
Providers should counsel patients that while Hayzen addresses critical micronutrient gaps, it does not replace balanced nutrition. Average dietary intake among pregnant U.S. adults falls short of recommendations for fiber (19.1 g vs. 28 g/day), potassium (2,310 mg vs. 4,700 mg/day), and calcium (725 mg vs. 1,000 mg/day). Supplementation complements—but never substitutes for—whole-food patterns rich in leafy greens, legumes, dairy or fortified plant milks, and fatty fish.
Finally, patients should be reminded that supplement quality varies widely. A 2023 investigation by ConsumerLab.com found that 22% of prenatal vitamins failed label claim testing for folate or iron—and 14% contained undeclared allergens. Choosing NSF- or USP-verified products like Hayzen mitigates these risks substantially.
Hayzen represents a meaningful evolution in prenatal nutrition—grounded in pharmacokinetics, third-party accountability, and real-world outcomes. Its formulation bridges gaps left by legacy products while maintaining rigorous safety standards. For clinicians, recommending Hayzen means prescribing with confidence in both biochemical precision and clinical responsiveness. For patients, it offers a tangible tool to support foundational aspects of reproductive health—starting well before the first ultrasound.
